Skip to main content

Neuropathix, Inc (NPTX)

OTCMKTS: NPTX · IEX Real-Time Price · USD
0.0410 0.0000 (0.00%)
Sep 22, 2021 9:30 AM EDT - Market closed
Market Cap3.54M
Revenue (ttm)32,000
Net Income (ttm)-4.25M
Shares Out87.98M
EPS (ttm)-0.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume0
Open0.0410
Previous Close0.0410
Day's Range0.0410 - 0.0410
52-Week Range0.0381 - 0.5450
Beta1.65
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About NPTX

Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary cannabinoid product platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild trauma...

IndustryBiotechnology
Founded2010
Employees7
Stock ExchangeOTCMKTS
Ticker SymbolNPTX
Full Company Profile

Financial Performance

Financial Statements

News

Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization...

Cosmeceutical Assets Include Company's Lead Anti-inflammatory OTC Cosmeceutical Compound called LEA™ (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine) Company's Strategy is to Enable Dermique to Focus...

1 month ago - Accesswire

Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board

DOYLESTOWN, PA / ACCESSWIRE / August 12, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announces today that it has...

1 month ago - Accesswire

Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other...

DOYLESTOWN, PA / ACCESSWIRE / July 20, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publicati...

2 months ago - Accesswire

Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharm...

DOYLESTOWN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today the publ...

4 months ago - GlobeNewsWire

Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead

DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today that it...

7 months ago - GlobeNewsWire

Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant

DOYLESTOWN, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced the publicati...

8 months ago - GlobeNewsWire

Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate

DOYLESTOWN, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (OTCQB: NPTX), (the “Company” or "Neuropathix"), a socially responsible pain management life sciences company, announced today that i...

9 months ago - GlobeNewsWire